Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non–Small Cell Lung Cancer

IMPORTANCE: Evidence regarding real-world effectiveness of therapies for patients with advanced non–small cell lung cancer (NSCLC) whose tumors are resistant to platinum-based chemotherapy is lacking. OBJECTIVE: To compare the effectiveness of the immune checkpoint inhibitors atezolizumab (programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramagopalan, Sreeram, Gupta, Alind, Arora, Paul, Thorlund, Kristian, Ray, Joshua, Subbiah, Vivek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590169/
https://www.ncbi.nlm.nih.gov/pubmed/34767024
http://dx.doi.org/10.1001/jamanetworkopen.2021.34299

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8590169/
https://www.ncbi.nlm.nih.gov/pubmed/34767024
http://dx.doi.org/10.1001/jamanetworkopen.2021.34299

Ejemplares similares